Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

Aerie Pharmaceuticals, Inc. announced that its sterile fill production facility in Athlone, Ireland has received approval from U.S. Food and Drug Administration (FDA) to produce Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful preapproval inspection of the facility and FDA review of the New Drug Application Prior Approval Supplement (PAS), which added the Athlone production facility as a drug product manufacturer for Rocklatan.